

# Annexes

**Annex 1: List of controlled substances in the 6 participating countries**

**Annex 2: Registry of medications subject to specific rules of prescription or delivery**

**Annex 3: Geographical repartition of the 6 pharmacies networks**

**Annex 4: List of the medications identified in the OSIAP survey in 2006-2007 according to the 2<sup>nd</sup>, 3<sup>rd</sup> and complete Anatomical Therapeutic and Chemical Classification.**

**Annex 5: oral communications and posters about the Osiap Europe project.**



## ANNEX 1

Each country has a separate system for listing and classifying substances. This table is extracted from the 2007 report of ECMDDA about the control of narcotics and psychotropics in Europe and concerns the application of international control and specific national controls in Belgium, France, Italy, Netherlands, Spain and Sweden.

Belgium lists controlled substances in the "Arrêté royal concernant le trafic des substances soporifiques et stupéfiants de 31 décembre 1930" and "Arrêté royal réglementant certaines substances psychotropes de 22 janvier 1998". In the above table, these have been abbreviated to S and P respectively. The latter is subdivided into Chapters I, II (1a, b, 2), III, IV. Some substances are also controlled by the "Arrêté royal du 12 avril 1974 relatif à certaines opérations concernant les substances à action hormonale, antihormonale, anabolisante, anti-infectieuse, antiparasitaire et anti-inflammatoire", listed above as A. Precursors are listed in the "Arrêté royal fixant des mesures afin d'empêcher le détournement de certaines substances pour la fabrication illicite de stupéfiants et de substances psychotropes du 23 octobre 1993".

France lists controlled substances in the "Arrêté du 22 février 1990 modifié fixant la liste des substances psychotropes", referred above as P and divided into parts 1, 2 and 3, and in the "Arrêté du 22 février 1990 modifié fixant la liste des substances classées comme stupéfiants", referred above as S and divided into Annexes I, II, III, IV. Precursors are listed in the "Décret n°96-1060 du 05 décembre 1996 fixant la liste des précurseurs chimiques de stupéfiants et de substances psychotropes soumis à contrôle", in Categories 1, 2,3 (PC1, PC2, PC3).

Italy classifies its substances in Tables I, II,A, and II,B, attached to the "DPR 309/90".

The Netherlands uses the Opium Act to list controlled substances in Schedules I and II. Precursors are all controlled by the 'Wet Voorkoming Misbruik Chemicalien' (WVMC), the 'Preventing Abuse of Chemicals Act'.

In Spain, narcotics are listed in the "ORDEN 31 de julio de 1967, que enmienda las Listas anexas al Convenio de 1961" (listed above as annexes EI, II, III, IV), and psychotropic substances are listed in "REAL DECRETO 2829/1977, de 6 de octubre, Regulador de las Sustancias y Preparados Medicinales Psicotrónicos así como su Fiscalización y Dispensación", with Annex 1 specified as PI, II, III, IV and Annex 2 (substances not listed in the lists I-IV) specified as P2. Precursors are controlled by "LEY 3/1996, de 10 de enero, sobre medidas de control de sustancias químicas catalogadas susceptibles de desvío para la fabricación ilícita de drogas", in categories 1, 2, 3.

Sweden lists its controlled substances in the law "LVFS 1997:12; Föreskrifter om ändring i Läkemedelsverkets föreskrifter om förteckningar över narkotika". They are classified as I, II, III, IV, V. Substances not officially classified as narcotics may be controlled by the "Ordinance on the Prohibition of Certain Goods Dangerous to Health (1999:58)", and are listed above as D. The law "Förordning (SFS 1992:1554) om kontroll av narkotika" lists precursors in I, II, III, listed above as PI, PII, PIII.

Substance Last updated	UN 61/72 Class	UN 71 Class	UN 88 Class	EC 273/2004 Aug 05 Class	Belgium Dec 06 Class	Italy April 07 Class	France July 02 Class	Netherlands Feb 07 Class	Spain July 02 Class	Sweden Oct 06 Class
<b>Substances controlled at international level</b>										
2C-B (BDMPEA)	-	II	-		P11.1b	I	SIII	I	P11	I
3-methylfentanyl	I	-	-		S	I	SI	I	EI, IV	II
3-methylthiofentanyl	I	-	-			I	SI	I	EI, IV	II
4-methylaminorex	-	I	-		P11.1a	I	SIII	I	PI	I
4-MTA	-	I	-		P11.2	I	SIII	I	PI	I
Acetorphine	I, IV	-	-			I	SI	I	EI	II
Acetyl-alpha-methylfentanyl	IV	-	-		S	I	SI	I	EI, IV	II
Acetyldihydrocodeine	II	-	-		S	I - II,A	SII	I	EII	II
Acetylmethadol	I	-	-		S		SI	I	EI	II
Alfentanil	I	-	-		S	II,A	SI	I	EI	II
Allobarbital	-	IV	-		P1111	II,B	P1	II	P1V	IV
Allylprodine	I	-	-		S	I	SI	I	EI	II
Alphacetylmethadol (LAAM)	I	-	-		S	I	SI	I	EI	II
Alphameprodine	I	-	-		S	I	SI	I	EI	II
Alphamethadol	I	-	-		S	I	SI	I	EI	II
Alpha-methylfentanyl	I,IV	-	-		S	I	SI	I	EI, IV	II
Alpha-methylthiofentanyl	I,IV	-	-			I	SI	I	EI, IV	II
Alphaprodine	I	-	-		S	I	SI	I	EI	II
Alprazolam	-	IV	-		P1111	II,B	P1	II	P1V	IV
Amfepramone (diethylpropion)	-	IV	-		P11.2	II,B	P1	II	P1V	II
Amfetamine (amphetamine)	-	II	-		P11.1b	I	SIII	I	P11	II
Amineptine		II			P11,1b	II,B		I		II
Aminorex	-	IV	-		P1111	I	P1	II	P1V	IV
Amobarbital	-	III	-		P1111	II,A	P1	II	P1111	IV
Anileridine	I	-	-		S	I	SI	I	EI	II
Barbital	-	IV	-		P1111	II,B	P1	II	P1V	IV
Benzethidine	I	-	-		S	I	SI	I	EI	II
Benzfetamine (benzphetamine)	-	IV	-		P1111	II,B	SIII, P2	II	P1V	II
Benzylmorphine	I	-	-		S	I	SI	I	EI	II

Betacetylmethadol	I	-	-	S	I	SI	I	EI	II
Beta-hydroxy-3-methylfentanyl	I, IV	-	-		I	SI	I	EI, IV	II
Beta-hydroxyfentanyl	I, IV	-	-		I	SI	I	EI, IV	II
Betameprodine	I	-	-	S	I	SI	I	EI	II
Betamethadol	I	-	-	S	I	SI	I	EI	II
Betaprodine	I	-	-	S	I	SI	I	EI	II
Bezitramide	I	-	-	S	I	SI	I	EI	II
Brolamfetamine (DOB)	-	I	-	PII.1a	I	SIII	I	PI	I
Bromazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Brotizolam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Buprenorphine	-	III	-	PIII / IV	I - II,A	P1	II	PIII	IV
Butalbital	-	III	-	PIII	II,B	P1	II	PIII	IV
Butobarbital	-	IV	-	PIII	II,B	P1	II	PIV	IV
Camazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Cannabis and Cannabis resin	IV	-	-	S	I	SI	II	EI, IV	I
Cannabis and cannabis resin and extracts and tinctures of cannabis	I	-	-	S	I		I		I
Cathine ((+)-norpseudo-ephedrine)	-	III	-	PIII	I	P1	II	PIII	II
Cathinone	-	I	-	PII.1a	I	SIII	I	PI	I
Chlordiazepoxide	-	IV	-	PIII	II,B	P1	II	PIV	IV
Clobazam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Clonazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Clonitazene	I	-	-	S	I	SI	I	EI	II
Clorazepate	-	IV	-	PIII	II,B	P1	II	PIV	IV
Clotiazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Cloxazolam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Coca leaf	I	-	-	S	I	SI	I	EI	II
Cocaine	I	-	-	S	I	SI	I	EI	II
Codeine	II	-	-	S	II,A	SII	I	EII	III
Codoxime	I	-	-		I	SI	I	EI	II
Concentrate of poppy straw	I	-	-	S	I	SI	I	EI	
Cyclobarbital	-	III	-	PIII	II,A	P1	II	PIII	IV
Delorazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Desomorphine	I, IV	-	-	S	I	SI	I	EI, IV	II
DET (Diethyltryptamine)	-	I	-	PII.1a	I	SIII	I	PI	I

Dexamfetamine (dexamphetamine)	-	II	-	PII.Ib	I	SIII	I	PII	II
Dextromoramide	I	-	-	S	I - II,A	SI	I	EI	II
Dextropropoxyphene	II	-	-	S	II,B	SII	I	EII	III
Diampromide	I	-	-	S	I	SI	I	EI	II
Diazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Diethylthiambutene	I	-	-	S	I	SI	I	EI	II
Difenoxin	I	-	-	S	I - II,A	SI	I	EI	II
Dihydrocodeine	II	-	-	S	II,A	SII	I	EII	II
Dihydroetorphine	I	-	-	S	I	SI	I	EI	II
Dihydromorphine	I	-	-	S	I	SI	I	EI	II
Dimenoxadol	I	-	-	S	I	SI	I	EI	II
Dimepheptanol	I	-	-	S	I	SI	I	EI	II
Dimethylthiambutene	I	-	-	S	I	SI	I	EI	II
Dioxaphetyl butyrate	I	-	-	S	I	SI	I	EI	II
Diphenoxylate	I	-	-	S	I - II,A	SI	I	EI	II
Dipipanone	I	-	-	S	I - II,A	SI	I	EI	II
DMA	-	I	-	PII.1a	I	SIII	I	PI	I
DMHP	-	I	-	PII.1a	I	SIII	I	PI	I
DMT	-	I	-	PII.1a	I	SIII	I	PI	I
DOET	-	I	-	PII.1a	I	SIII	I	PI	I
Dronabinol (delta-9-tetrahydro-cannabinol and its stereochemical variants)	-	II	-	PII.1b	I - II,B	SIV	I	PII	
Drotebanol	I	-	-		I	SI	I	EI	II
Ecgonine	I	-	-	S	I	SI	I	EI	II
Estazolam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Ethchlorvynol	-	IV	-	PIII	I	P1	II	PIV	IV
Ethinamate	-	IV	-	PIII	II,B	P1	II	PIV	IV
Ethyl Loflazepate	-	IV	-	PIII	II,B	P1	II	PIV	IV
Ethylmethylthiambutene	I	-	-	S	I	SI	I	EI	II
Ethylmorphine	II	-	-	S	I - II,A	SII	I	EII	III
Eticyclidine (PCE)	-	I	-	PII.1a	I	SIII	I	PI	I
Etilamfetamine (N-ethylamphetamine)	-	IV	-	PII.2	I	SIII	II	PIV	II
Etonitazene	I	-	-	S	I	SI	I	EI	II
Etorphine	I, IV	-	-		I	SI	I	EI	II

Etoxidine	I	-	-	S	I	SI	I	EI	II
Etryptamine	-	I	-	P11.1a	I	SIII	I	PI	I
Fencamfamine	-	IV	-	P111	II,B	P1	II	PIV	II
Fenetylline	-	II	-	P11.1b	I	SIII	I	P11	II
Fenproporex	-	IV	-	P11.2	II,B	P1	II	PIV	II
Fentanyl	I	-	-	S	II,A	SI	I	EI	II
Fludiazepam	-	IV	-	P111	II,B	P1	II	PIV	II
Flunitrazepam	-	III	-	P11,2	I - II,A	P1	II	P111	IV
Flurazepam	-	IV	-	P111	II,B	P1	II	PIV	IV
Furethidine	I	-	-	S	I	SI	I	EI	II
GHB	-	IV	-	P11.2	I - II,B	SIII	II	PIV	II
Glutethimide	-	III	-	P111	II,A	P1	II	P111	IV
Halazepam	-	IV	-	P111	II,B	P1	II	PIV	IV
Haloxazolam	-	IV	-	P111	II,B	P1	II	PIV	IV
Heroin	I, IV	-	-	S	I	SI	I	EI, IV	I
Hydrocodone	I	-	-	S	II,A	SI	I	EI	II
Hydromorphenol	I	-	-	S	I	SI	I	EI	II
Hydromorphone	I	-	-	S	II,A	SI	I	EI	II
Hydroxypethidine	I	-	-	S	I	SI	I	EI	II
Isomethadone	I	-	-	S	I	SI	I	EI	II
Ketazolam	-	IV	-	P111	II,B	P1	II	PIV	IV
Ketobemidone	I, IV	-	-	S	I	SI	I	EI, IV	II
Lefetamine (SPA)	-	IV	-	P111	II,B	P1	II	PIV	II
Levamphetamine (levamphetamine)	-	II	-	P11.1b	I	SIII	I	P11	II
levomethamphetamine	-	II	-	P11.1b	I	SIII	I	P11	II
Levomethorphan	I	-	-	S	I	SI	I	EI	II
Levomoramide	I	-	-	S	I	SI	I	EI	II
Levophenacylmorphan	I	-	-	S	I	SI	I	EI	II
Levorphanol	I	-	-	S	I - II,A	SI	I	EI	II
Loprazolam	-	IV	-	P111	II,B	P1	II	PIV	IV
Lorazepam	-	IV	-	P111	II,B	P1	II	PIV	IV
Lormetazepam	-	IV	-	P111	II,B	P1	II	PIV	IV
Lysergide (LSD, LSD-25)	-	I	-	P11.1a	I	SIII	I	PI	I
Mazindol	-	IV	-	P111	II,B	P1	II	PIV	II
MDMA	-	I	-	P11.1a	I	SIII	I	PI	I

Mecloqualone	-	II	-	P11.1b	II,A	SIII	I	P11	II
Medazepam	-	IV	-	P111	II,B	P1	II	P1V	IV
Mefenorex	-	IV	-	P11.2	II,B	SIII, P2	II	P1V	II
Meprobamate	-	IV	-	P111	II,B	P1	II	P1V	IV
Mescaline	-	I	-	P11.1a	I	SIII	I	P1	I
Mesocarb	-	IV	-	P111	I	P1	II	P1V	IV
Metamfetamine (methamphetamine)	-	II	-	P11.1b	I	SIII	I	P11	II
Metamfetamine racemate	-	II	-	P11.1b	I	SIII	I	P11	II
Metazocine	I	-	-	S	I	S1	I	E1	II
Methadone	I	-	-	S	I - II,A	S1	I	E1	II
Methadone intermediate	I	-	-	S	I	S1	I	E1	II
Methaqualone	-	II	-	P11.1b	II,A	SIII	I	P11, P1V	II
Methcathinone	-	I	-	P11.1a	I	SIII	I	P1	I
Methyldesorphine	I	-	-	S	I	S1	I	E1	II
Methyldihydromorphine	I	-	-	S	I	S1	I	E1	II
Methylphenidate	-	II	-	P11.1b	I - II,A	SIII	I	P11	II
Methylphenobarbital	-	IV	-	P111	II,B	P1	II	P1V	IV
Methyprylon	-	IV	-	P111	II,B	P1	II	P1V	IV
Metopon	I	-	-	S	I	S1	I	E1	II
Midazolam	-	IV	-	P111	II,B	P1	II	P1V	IV
MMDA	-	I	-	P11.1a	I	SIII	I	P1	I
Moramide intermediate	I	-	-	S		S1	I	E1	II
Morpheridine	I	-	-	S	I	S1	I	E1	II
Morphine	I	-	-	S	I - II,A	S1	I	E1	II
Morphine methobromide and other pentavalent nitrogen morphine derivatives, one of which is Codeine-N-Oxide	I	-	-		I	S1	I	E1	II
Morphine-N-oxide	I	-	-	?	I	S1	I	E1	II
MPPP (1-methyl-4-phenyl-4-piperidinol propionate (ester))	I, IV	-	-	S	I	S1	I	E1, IV	I
Myrophine	I	-	-	S	I	S1	I	E1	II
N-ethyl MDA (MDE) MDEA	-	I	-	P11.1a	I	SIII	I	P1	I
N-hydroxy MDA	-	I	-	P11.1a	I	SIII	I	P1	I
Nicocodine	II	-	-	S	I - II,A	SII	I	EII	III



Nicodicodeine	II	-	-		I - II,A	SII	I	EII	III
Nicomorphine	I	-	-	S	I	SI	I	EI	II
Nimetazepam	-	IV	-	PIII	II,B	P1	II	PIV	II
Nitrazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Noracymethadol	I	-	-	S	I	SI	I	EI	II
Norcodeine	II	-	-	S	I -II,A	SII	I	EII	III
Nordazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Norlevorphanol	I	-	-	S	I	SI	I	EI	II
Normethadone	I	-	-	S	I	SI	I	EI	II
Normorphine	I	-	-	S	I	SI	I	EI	II
Norpipanone	I	-	-	S	I	SI	I	EI	II
Opium	I	-	-	S	I	SI	I	EI	II
Oripavine	I	-	-						
Oxazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Oxazolam	-	IV	-	S	II,B	P1	II	PIV	IV
Oxycodone	I	-	-	S	II,A	SI	I	EI	II
Oxymorphone	I	-	-	S	II,A	SI	I	EI	II
Papaver Somniferum							N A		
Para-fluorofentanyl	I, IV	-	-		I	SI	I	EI, IV	I
Parahexyl	-	I	-	P1I.1a	I	SIII	I	PI	I
Pemoline	-	IV	-	PIII / IV	I	P1	II	PIV	II
Pentazocine	-	III	-	PIII / IV	II,B	SIII	II	PIII	III
Pentobarbital	-	III	-	PIII	II,A	P1	II	PIII	IV
PEPAP (1-phenethyl-4-phenyl-4-piperidinol acetate (ester))	I, IV	-	-	S	I	SI	I	EI, IV	I
Pethidine	I	-	-	S	I - II,A	SI	I	EI	II
Pethidine intermediate A	I	-	-	S	I	SI	I	EI	II
Pethidine intermediate B	I	-	-	S	I	SI	I	EI	II
Pethidine intermediate C	I	-	-	S	I	SI	I	EI	II
Phenadoxone	I	-	-	S	I	SI	I	EI	II
Phenampromide	I	-	-	S	I	SI	I	EI	II
Phenazocine	I	-	-	S	I	SI	I	EI	II
Phencyclidine (PCP)	-	II	-	P1I.1b	I	SIII	I	P1I	II
Phendimetrazine	-	IV	-	PIII / IV	II,B	SIII	II	PIV	II
Phenmetrazine	-	II	-	P1I.1b	I	SIII	I	P1I	II

Phenobarbital	-	IV	-	S	II,B	P1	II	PIV	IV
Phenomorphin	I	-	-	S	I	SI	I	EI	II
Phenoperidine	I	-	-	S	I	SI	I	EI	II
Phentermine	-	IV	-	PIII / IV	II,B	SIII, P2	II	PIV	II
Pholcodine	II	-	-	S	I - II,A	SII	I	EII	III
Piminodine	I	-	-	S	I	SI	I	EI	II
Pinazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Pipradrol	-	IV	-	P1I.2	II,B	P1	II	PIV	II
Piritramide	I	-	-	S	I	SI	I	EI	II
PMA	-	I	-	P1I.1a	I	SIII	I	PI	I
Prazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Proheptazine	I	-	-	S	I	SI	I	EI	II
Properidine	I	-	-	S	I	SI	I	EI	II
Propiram	II	-	-		I - II,A	SII	I	EII	III
Psilocine, psilotsin	-	I	-	P1I.1a	I	SIII	I	PI	I
Psilocybine	-	I	-	P1I.1a	I	SIII	I	PI	I
Pyrovalerone	-	IV	-	PIII	II,B	SIII	II	PIV	II
Racemethorphan	I	-	-	S	I	SI	I	EI	II
Racemoramide	I	-	-	S	I	SI	I	EI	II
Racemorphan	I	-	-	S	I	SI	I	EI	II
Remifentanil	I	-	-	S	II,A	SI	I	EI	II
Rolicyclidine (PHP, PCPY)	-	I	-	P1I.1a	I	SIII	I	PI	I
Secbutabarbital	-	IV	-	PIII	II,B	P1	II	PIV	IV
Secobarbital	-	II	-	P1I.1b	II,A	SIII	I	P1I, P1II	II
STP, DOM	-	I	-	P1I.1a	I	SIII	I	PI	I
Sufentanil	I	-	-	S	II,A	SI	I	EI	II
Temazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Tenamfetamine (MDA)	-	I	-	P1I.1a	I	SIII	I	PI	I
Tenocyclidine (TCP)	-	I	-	P1I.1a	I	SIII	I	PI	I
(THC) Tetrahydrocannabinol, isomers and their stereochemical variants	-	I	-	P1I.1a	I - II,B	SIV	I	PI	I
Tetrazepam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Thebacon	I	-	-	S	I	SI	I	EI	II
Thebaine	I	-	-	S	I - II,A	SI	I	EI	II
Thiofentanyl	I, IV	-	-		II,A	SI	I	EI, IV	I

Tilidine	I	-	-	S	I	SI	I	EI	II
TMA	-	I	-	PII,10	I	SIII	I	PI	I
Triazolam	-	IV	-	PIII	II,B	P1	II	PIV	IV
Trimeperidine	I	-	-	S	I	SI	I	EI	II
Vinylbital	-	IV	-	PIII	II,B	P1	II	PIV	IV
Zipeprol	-	II	-	PII.1b	II,A	SIII	I	P2	IV
Zolpidem	-	IV	-	PIII	II,B	P1	II	PIV	IV

Precursors controlled at International level

3,4-methylenedioxyphenyl-2-propanone				I	CAT 1	cat. 1		WVMC		PI
Acetic anhydride	-	-	II	II	CAT 2	cat.2	PC2	WVMC	2	PII
Acetone	-	-	II	III	CAT 3	cat.3	PC3	WVMC	3	PIII
Anthranilic acid	-	-	II	II	CAT 2	cat.2	PC2	WVMC	2	PII
Ephedrine	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Ergometrine	-	-	I	I	CAT 2	cat.1	PC1	WVMC	1	PI
Ergotamine	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Ethyl ether	-	-	II	III	CAT 3	cat.3	PC3	WVMC	3	PIII
Hydrochloric acid (HCl)	-	-	II	III	CAT 3	cat.3	PC3	WVMC	3	PIII
Isosafrole	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Lysergic acid	-	-	I	I	CAT 1	cat.1	SIV, PC1	WVMC	1	PI
Methyl ethyl ketone MEK (BUTANONE)	-	-	II	III	CAT 3	cat.3	PC3	WVMC	3	PIII
N-Acetylanthranilic acid	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Norephedrine				I	CAT 1, PIV	cat.1		WVMC		PI
Phenylacetic acid	-	-	II	II	CAT 2	cat.2	PC2	WVMC	2	PII
Phenylacetone (1-Phenyl-2-Propanon)	-	-	I	I	CAT 1	cat.1	SIV, PC1	WVMC	1	PI
Piperidine	-	-	II	II	CAT 2	cat.2	PC2	WVMC	2	PII
Piperonal	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Potassium permanganate	-	-	II	II	CAT 2	cat.2	PC3	WVMC	3	PII
Pseudoephedrine	-	-	I	I	CAT 1	cat.1	PC1	WVMC	1	PI
Safrole	-	-	I	I	CAT 3	cat.1	PC1	WVMC	1	PI
Sulphuric acid	-	-	II	III	CAT 3	cat.3	PC3	WVMC	3	PIII
Toluene	-	-	II	III		cat.3	PC3	WVMC	3	PIII

## Annex 2: Registry of medications subject to specific rules of prescription or delivery

<i>ATC 7</i>	<i>international non-proprietary name</i>	<i>Convention</i>	<i>DDD</i>	<i>unit of DDD</i>	<i>route of administration</i>
R05DA12	acetyldihydrocodeine	1961			
R05DA22	acetyldihydrocodeine, combinations	1961			
N05CC03	acetylglycinamide chloral hydrate				
N02BA71	acetylsalicylic acid, comb with psycholeptics				
N05BA07	adinazolam				
N06AX22	Agomelatine				
	<b>alfacetylmethadol</b>	1961			
N01AX05	alfaxalone				
<b>N01AH02</b>	<b>alfentanil</b>	1961	<b>N A</b>		parenteral
N05CA21	allobarbital				
<b>N05BA12</b>	<b>alprazolam</b>	1971	<b>1</b>	<b>mg</b>	orally
N06AX12	amfebutamone				
<b>N06BA01</b>	<b>amfetamine</b>	1971	<b>15</b>	<b>mg</b>	or / par
N06AA19	amineptine	1971			
N02BB03	aminophenazone				
N02BB53	aminophenazone, combinations excl psycholeptics				
N02BB73	aminophenazone, combinations with psycholeptics				
<b>N05AL05</b>	<b>amisulpride ***</b>	N I	<b>400</b>	<b>mg</b>	orally
N06AA09	amitriptyline				
<b>N05CA02</b>	<b>Amobarbital</b>	1971	<b>100</b>	<b>mg</b>	or / par
N06AA17	amoxapine				
N01AA01	anesthetic ether (diethyl ether)				
N01AH05	anileridine	1961			
R01AC04	antazoline				
N05CA05	aprobarbital				
N05CM12	apronal				
<b>N05AX12</b>	<b>aripiprazole ***</b>	N I	<b>15</b>	<b>mg</b>	orally
N06BA09	atomoxetine				
R01AC03	azelastine				
M03BX01	baclofen				
N05CA04	barbital	1971			
N05CB02	barbiturates in combination with other drugs				
R01AD01	beclometasone				
R05DB02	benproperine				
N05BD01	benzocetamine				
R05DB01	benzonatate				
R01AD06	betamethasone				
<b>N02AC05</b>	<b>bezitramide</b>	1961	<b>15</b>	<b>mg</b>	orally
R05DB12	bibenzonium bromide				
N06AX08	bifemelane				
M09AX20	bone extract				

<b>N05BA08</b>	<b>bromazepam</b>	1971	<b>10</b>	<b>mg</b>	orally
N05CM11	bromides				
N05CM03	bromisoval				
<b>N05CD09</b>	<b>brotizolam</b>	1971	<b>0,25</b>	<b>mg</b>	orally
N02BE74	bucetin, combinations with psycholeptics				
R01AD05	budesonide				
<b>N02AE01</b>	<b>buprenorphine</b>	1971	<b>1,2</b>	<b>mg</b>	orally
<b>N02AE01</b>	<b>buprenorphine</b>	1971	<b>1,2</b>	<b>mg</b>	parenteral
<b>N02AE01</b>	<b>buprenorphine</b>	1971	<b>1,2</b>	<b>mg</b>	TD/subl
N02AE01	buprenorphine	1971			
N02AE02	Buprenorphine	1971			
<b>N07BC01</b>	<b>buprenorphine HD</b>	1971	<b>8</b>	<b>mg</b>	subl
N07BC51	Buprenorphine, combinations	1971			
N07BA02	bupropion				
<b>N05BE01</b>	<b>buspirone</b>	N I	<b>30</b>	<b>mg</b>	orally
<b>N05CA07</b>	<b>Butalbital</b>	1971	<b>100</b>	<b>mg</b>	orally
R05DB13	butamirate				
<b>N05CA03</b>	<b>butobarbital</b>	1971	<b>150</b>	<b>mg</b>	rectal
N02AF01	butorphanol				
N06AA15	butriptyline				
R01AX01	calcium hexamine thiocyanate				
N05BA15	camazepam	1971			
N05BB02	captodiame				
N05CM04	carbromal				
M03BA02	carisoprodol				
M03BA52	carisoprodol, combinations excl psycholeptics				
M03BA72	carisoprodol, combinations with psycholeptics				
N05CC01	chloral hydrate				
N05CC02	chloralodol				
N05CC06	chloralose				
<b>N05BA02</b>	<b>chlordiazepoxide</b>	1971	<b>30</b>	<b>mg</b>	orally
M03BB02	chlormezanone				
M03BB52	chlormezanone, combinations excl psycholeptics				
M03BB72	chlormezanone, combinations with psycholeptics				
N01AB02	chloroform				
M03BB03	chlorzoxazone				
M03BB53	chlorzoxazone, combinations excl psycholeptics				
M03BB73	chlorzoxazone, combinations with psycholeptics				
M09AX25	chondroitin sulfate				
M09AB01	chymopapain				
N05CD13	Cinolazepam				
<b>N05BA09</b>	<b>clobazam</b>	1971	<b>20</b>	<b>mg</b>	orally
R05DB03	clobutinol				
R05DB10	clofedanol				
N05CM02	clomethiazole				
N05CX04	clomethiazole, combinations				

N06AA04	clomipramine				
<b>N03AE01</b>	<b>clonazepam</b>	1971	<b>8</b>	<b>mg</b>	orally
<b>N03AE01</b>	<b>clonazepam</b>	1971	<b>8</b>	<b>mg</b>	parenteral
R05DB21	cloperastine				
<b>N05BA05</b>	<b>clorazepate combinations</b>	1971	<b>20</b>	<b>mg</b>	orally
<b>N05BA05</b>	<b>clorazepate potassium</b>	1971	<b>20</b>	<b>mg</b>	orally
<b>N05BA05</b>	<b>clorazepate potassium</b>	1971	<b>100</b>	<b>mg</b>	parenteral
<b>N05BA06</b>	<b>clorazepate potassium (20 mg)</b>	1971	<b>20</b>	<b>mg</b>	orally
<b>N05BA05</b>	<b>clorazepate potassium (50 mg)</b>	1971	<b>20</b>	<b>mg</b>	orally
<b>N05BA21</b>	<b>clotiazepam</b>	1971	<b>10</b>	<b>mg</b>	orally
N05BA22	cloxazolam	1971			
<b>N05AH02</b>	<b>clozapine</b>	N I	<b>300</b>	<b>mg</b>	orally
R05DA04	codeine	1961			
<b>N02AA08</b>	<b>codeine (&gt;100 mg or 2,5%)</b>	1961	<b>150</b>	<b>mg</b>	orally
N02AA79	codeine, comb. with psycholeptics	1961			
N02AA59	codeine, combinations	1961			
R01AX30	combinations				
R05DA20	combinations				
R05DB20	combinations				
N05CB01	combinations of barbiturates				
R05FB02	cough suppressants and expectorants				
R05FB01	cough suppressants and mucolytics				
R01AC01	cromoglicic acid				
R01AC51	cromoglicic acid, combinations				
<b>N05CA10</b>	<b>Cyclobarbitol</b>	1971	<b>200</b>	<b>mg</b>	orally
M03BX08	cyclobenzaprine				
R01AA02	cyclopentamine				
N01AB07	desflurane				
N06AA01	desipramine				
R01AD03	dexamethasone				
R01AD53	dexamethasone, combinations				
<b>N06BA02</b>	<b>dexamfetamine</b>	1971	<b>15</b>	<b>mg</b>	orally
N05CM18	Dexmedetomidine				
R05DA09	dextromethorphan				
R05DA21	dextromethorphan, combinations				
<b>N02AC01</b>	<b>dextromoramide</b>	1961	<b>20</b>	<b>mg</b>	or / par
<b>N02AC01</b>	<b>dextromoramide</b>	1961	<b>40</b>	<b>mg</b>	rectal
<b>N02AC04</b>	<b>dextropropoxyphen (&gt;135 mg or 2,5%)</b>	1961	<b>200</b>	<b>mg</b>	as chloride
N02AC54	dextropropoxyphene, comb excl psycholept	1961			
N02AC74	dextropropoxyphene, comb with psycholeptics	1961			
N02AX03	dezocine				
N02AA09	diamorphine				
<b>N05BA01</b>	<b>diazepam</b>	1971	<b>10</b>	<b>mg</b>	or / par
<b>N05BA01</b>	<b>diazepam</b>	1971	<b>10</b>	<b>mg</b>	rectal
N06AA08	dibenzepin				
R05DB16	dibunate				

N05CC04	dichloralphenazone				
A07DA04	difenoxin	1961			
<b>A07DA01</b>	<b>difenoxylaai (&gt;2,5 mg or without atropine)</b>	1961	<b>15</b>	<b>mg</b>	orally
<b>N02AA08</b>	<b>dihydrocodeïne (&gt;100 mg or 2,5%)</b>	1961	<b>150</b>	<b>mg</b>	orally
N02AA58	dihydrocodeine, combinations	1961			
R05DA13	dihydrocodeinetartraat	1961			
R05DA11	dimemorfan				
N06AA18	dimetacrine				
R05DB28	dimethoxanaat				
N05CX06	dipiperonylaminoethanol, combinations				
N02BA79	dipyrocytyl, combinations with psycholeptics				
N06AA16	dosulepin				
N05CD12	doxefazepam				
N06AA12	doxepin				
N01AX01	droperidol				
R05DB19	dropropizine				
R05DB17	droxypropine				
N06AX21	Duloxetine				
N05CX05	emepronium, combinations				
N05BC03	emylcamate				
N01AB04	enflurane				
R01AA03	ephedrine				
R01AB05	ephedrine				
R01BA30	ephedrine, combinations with				
R01AA14	epinephrine				
R05DB29	erysimum officinale				
<b>N05CD04</b>	<b>estazolam</b>	1971	<b>3</b>	<b>mg</b>	orally
N05CA20	etalobarbital				
N05CM08	ethchlorvynol				
N02BA77	ethenzamide, combinations with psycholeptics				
<b>N05BA18</b>	<b>ethyl loflazepate</b>	1971	<b>2</b>	<b>mg</b>	orally
<b>R05DA01</b>	<b>ethylmorphine (&gt;100 mg or 2,5%)</b>	1961	<b>50</b>	<b>mg</b>	orally
R05DB30	ethylorthoformiaat				
<b>N05BX03</b>	<b>etifoxine</b>	N I	<b>N A</b>		orally
N05BA19	etizolam				
N01AX07	etomidate				
M03BA05	febarbamate				
R05DB14	fedrilate				
N06BA06	fencamfamin	1971			
N06BA10	Fenetylline	1971			
R01AA12	fenoxazoline				
N06BA08	fenozolone				
<b>N01AH01</b>	<b>fentanyl</b>	1961	<b>N A</b>		parenteral
<b>N02AB03</b>	<b>fentanyl</b>	1961	<b>0,6</b>	<b>mg</b>	orally
<b>N02AB03</b>	<b>fentanyl</b>	1961	<b>1,2</b>	<b>mg</b>	TD
N01AH51	fentanyl, combinations	1961			

N02BG04	floctafenine				
N05BA17	fludiazepam	1971			
R01AD04	flunisolide				
<b>N05CD03</b>	<b>flunitrazepam</b>	1971	<b>1</b>	<b>mg</b>	orally
<b>N05CD03</b>	<b>flunitrazepam</b>	1971	<b>1</b>	<b>mg</b>	parenteral
N02BG07	flupirtine				
<b>N05CD01</b>	<b>flurazepam</b>	1971	<b>N A</b>		orally
R01AD08	fluticasone				
R01AX08	framycetin				
N05CX30	fytotherapy				
N05BX02	gedocarnil				
N06AX19	gepirone				
N02BG03	glafenine				
N05CE01	glutethimide	1971			
<b>N05BA13</b>	<b>halazepam</b>	1971	<b>0,1</b>	<b>g</b>	orally
N01AB01	halothane				
N05CA11	heptabarbital				
R01AX07	hexamidine				
N05CM10	hexapropymate				
N01AF02	hexobarbital				
N05CA16	hexobarbital				
M09AX01	hyaluronic acid				
R05DA03	hydrocodone				
R01AD60	hydrocortisone, combinations				
<b>N02AA03</b>	<b>hydromorphone</b>	1961	<b>4</b>	<b>mg</b>	or / par
<b>N02AA03</b>	<b>hydromorphone</b>	1961	<b>20</b>	<b>mg</b>	orally
<b>N02AA03</b>	<b>hydromorphone</b>	1961	<b>4</b>	<b>mg</b>	rectal
N02AG04	hydromorphone and antispasmodics	1961			
M09AA01	hydroquinine				
N01AX11	hydroxybutyric acid				
<b>N05BB01</b>	<b>hydroxyzine</b>	N I	<b>75</b>	<b>mg</b>	orally
N05BB51	hydroxyzine, combinations				
N06AX20	hypericin				
N06AA02	imipramine				
N06AA03	imipramine oxide				
R01AX03	ipratropium bromide				
N06AA13	iprindole				
R05DB04	isoaminile				
R01AD51	isoflupredone, combinations				
N01AB06	isoflurane				
N01AX03	ketamine				
<b>N05BA10</b>	<b>ketazolam</b>	1971			
N02AB01	ketobemidone	1961			
N02AG02	ketobemidone and antispasmodics	1961			
<b>N07BC03</b>	<b>levacetylmethadol</b>				
R01AC02	levocabastine				



R05DB27	levodropropizine				
N06AA07	lofepramine				
N07BC04	lofexidine				
A07DA03	loperamide				
A07DA05	loperamide oxide				
A07DA53	loperamide, combinations				
<b>N05CD11</b>	<b>loprazolam</b>	1971	<b>1</b>	<b>mg</b>	orally
<b>N05BA06</b>	<b>lorazepam</b>	1971	<b>2,5</b>	<b>mg</b>	orally
N05BA56	lorazepam, combinations	1971			
<b>N05CD06</b>	<b>lormetazepam</b>	1971	<b>1</b>	<b>mg</b>	orally
N06AA21	maprotiline				
N05BC04	mebutamate				
N05BA03	medazepam	1971			
N06AX13	medifoxamine				
N05CM17	Melatonin				
N06AA14	melitracen				
M03BX06	mephenesin				
N05BX01	mephenoxalone				
M03BB50	mephenoxalone, comb excl psycholeptica				
<b>N05BC01</b>	<b>meprobamate</b>	1971	<b>1200</b>	<b>mg</b>	orally
<b>N05BC51</b>	<b>meprobamate, combinations</b>	1971	<b>1200</b>	<b>mg</b>	orally
N05CX01	meprobamate, combinations	1971			
R05DB22	meprotixol				
R01AX12	mesna				
<b>N06BA03</b>	<b>metamfetamine</b>	1971	<b>15</b>	<b>mg</b>	orally
N02BB02	metamizole sodium				
N02BB52	metamizole sodium, combinations excl psycholeptics				
N02BB72	metamizole sodium, combinations with psycholeptics				
N02AC02	methadone	1961			
<b>N07BC02</b>	<b>methadone</b>	1961	<b>25</b>	<b>mg</b>	orally
<b>N07BC02</b>	<b>methadone</b>	1961	<b>25</b>	<b>mg</b>	parenteral
N02AC52	methadone, comb. excl. psycholeptics	1961			
N05CM01	methaqualone	1971			
N05CX02	methaqualone, combinations	1971			
M03BA03	methocarbamol				
M03BA53	methocarbamol, combinations excl psycholeptics				
M03BA73	methocarbamol, combinations with psycholeptics				
N01AF01	methohexital				
N05CA15	methohexital				
N01AB03	methoxyflurane				
N05CM15	methylpentynol				
N05CX03	methylpentynol, combinations				
<b>N06BA04</b>	<b>methylphenidate</b>	1971	<b>30</b>	<b>mg</b>	orally
N05CE02	methyprylon				

R01AA10	metizoline				
N06AX03	mianserin				
<b>N05CD08</b>	<b>midazolam</b>	1971	<b>15</b>	<b>mg</b>	orally
<b>N05CD08</b>	<b>midazolam</b>	1971	<b>15</b>	<b>mg</b>	parenteral
N06AX17	milnacipran				
N06AX07	minaprine				
N06AX11	mirtazapine				
<b>N06BA07</b>	<b>modafinil</b>	N I	<b>300</b>	<b>mg</b>	orally
R01AD09	mometasone				
R05DB25	morclofone				
<b>N02AA01</b>	<b>morphine</b>	1961	<b>100</b>	<b>mg</b>	orally
<b>N02AA01</b>	<b>morphine</b>	1961	<b>30</b>	<b>mg</b>	parenteral
<b>N02AA01</b>	<b>morphine (&gt;0,2% morphine)</b>	1961	<b>30</b>	<b>mg</b>	rectal
N02AG01	morphine and antispasmodics	1961			
A07DA52	morphine, combinations	1961			
N02AA51	morphine, combinations	1961			
R01AX06	mupirocin				
N02AF02	nalbufine				
R01AA08	naphazoline				
R01AB02	naphazoline				
N01AG01	narcobarbital				
R01AC07	nedocromil				
N06AX06	nefazodone				
N02BG06	nefopam				
R05DB26	nepinalone				
N05CM16	niaprazine				
<b>N02AA04</b>	<b>nicomorphine</b>	1961	<b>30</b>	<b>mg</b>	or / par
<b>N02AA04</b>	<b>nicomorphine</b>	1961	<b>30</b>	<b>mg</b>	rectal
N02BB05	nifenazone				
<b>N05CD02</b>	<b>nitrazepam</b>	1971	<b>5</b>	<b>mg</b>	orally
N01AX13	nitrous oxide				
N06AX04	nomifensine				
<b>N05BA16</b>	<b>nordazepam</b>	1971	<b>15</b>	<b>mg</b>	orally
R05DA06	normethadone				
N06AA10	nortriptyline				
R05DA07	noscapine				
<b>N05AH03</b>	<b>olanzapine ***</b>	N I	<b>10,0</b>	<b>mg</b>	orally
<b>N05AH03</b>	<b>olanzapine ***</b>	N I	<b>10,0</b>	<b>mg</b>	parenteral
R01AC08	Olopatadine				
N06AA05	opipramol				
<b>A07DA02</b>	<b>opium (&gt;0,2% morphine)</b>	1961	<b>100</b>	<b>mg</b>	orally
<b>N02AA02</b>	<b>opium (&gt;0,2% morphine)</b>	1961			
R05DA05	opium alkaloids with morphine	1961			
R05FA02	opium derivatives and expectorants	1961			
R05FA01	opium derivatives and mucolytics	1961			
M03BC01	orphenadrine (citrate)				

M03BC51	orphenadrine, combinations				
N06AX10	oxaflorazone				
<b>N05BA04</b>	<b>oxazepam</b>	1971	<b>50</b>	<b>mg</b>	orally
R05DB09	oxeladin				
N06AX01	oxitriptan				
R05DB07	oxolamine				
<b>N02AA05</b>	<b>oxycodone</b>	1961	<b>75</b>	<b>mg</b>	orally
<b>N02AA05</b>	<b>oxycodone</b>	1961	<b>30</b>	<b>mg</b>	parenteral
R01AA05	oxymetazoline				
R01AB07	oxymetazoline				
N02AA10	papaveretum				
N02BE71	paracetamol, combinations with psycholeptics				
N05CC05	paraldehyde				
N05CM20	passiflora				
N06BA05	pemoline	1971			
<b>N02AD01</b>	<b>pentazocine</b>	1971	<b>200</b>	<b>mg</b>	or / par
<b>N05CA01</b>	<b>Pentobarbital</b>	1971	<b>100</b>	<b>mg</b>	or / par
<b>N05CA01</b>	<b>Pentobarbital</b>	1971	<b>100</b>	<b>mg</b>	rectal
R05DB05	pentoxyverine				
<b>N02AB02</b>	<b>pethidine</b>	1961	<b>400</b>	<b>mg</b>	or and rectal
<b>N02AB02</b>	<b>pethidine</b>	1961	<b>400</b>	<b>mg</b>	parenteral
N02AG03	pethidine and antispasmodics	1961			
N02AB72	pethidine, comb with psycholeptics	1961			
N02AB52	pethidine, comb. excl. psycholeptics	1961			
N02BE73	phenacetin, combinations with psycholeptics				
N02AD02	phenazocine				
N02BB01	phenazone	1961			
N02BB51	phenazone, combinations excl psycholeptics				
N02BB71	phenazone, combinations with psycholeptics				
<b>N03AA02</b>	<b>phenobarbital</b>	1971	<b>0,1</b>	<b>g</b>	orally
N01AH04	phenoperidine	1961			
M03BA01	phenprobamate				
M03BA51	phenprobamate, combinations excl psycholeptics				
M03BA71	phenprobamate, combinations with psycholeptics				
R01BA53	phenylefrine, combinations				
R01AA04	phenylephrine				
R01AB01	phenylephrine				
R01BA03	phenylephrine				
R01BA01	phenylpropranolamine				
R01BA51	phenylpropranolamine, combinations				
M03BX30	phenylramidol				
<b>R05DA08</b>	<b>pholcodine&gt;100mg ou&gt;2,5</b>	1961	<b>50</b>	<b>mg</b>	orally
<b>N05BA14</b>	<b>pinazepam</b>	1971			
R05DB11	pipazetate				
R05DB23	piperidone				
<b>N02AC03</b>	<b>piritramide</b>	1961	<b>45</b>	<b>mg</b>	parenteral

N06AX15	pivagabine				
<b>N05BA11</b>	<b>prazepam</b>	1971	<b>30</b>	<b>mg</b>	orally
R01AD52	prednisolon, combinations				
R01AD02	prednisolone				
R05DB18	prenoxdiazine				
M03BX03	pridinol				
N01AX04	propanidid				
N05CM06	propiomazine				
N01AX10	propofol				
N02BB04	propyphenazone				
N02BB54	propyphenazone, combinations excl psycholeptics				
N02BB74	propyphenazone, combinations with psycholeptics				
N06AA11	protriptyline				
N05CA22	proxibarbal				
R01BA02	pseudoephedrine				
R01BA52	pseudoephedrine, combinations				
N05CE03	pyrithyldione				
<b>N05CD10</b>	<b>quazepam</b>	N I	<b>15</b>	<b>mg</b>	orally
<b>N05AH04</b>	<b>quetiapine ***</b>	N I	<b>400</b>	<b>mg</b>	orally
N02BG50	quinine, combinations				
M09AA72	quinine, combinations with psycholeptics				
N06AA23	quinupramine				
N06AX18	reboxetine				
<b>N01AH06</b>	<b>remifentanil</b>	1961	<b>N A</b>		parenteral
N05CA12	reposal				
R01AX02	retinol				
N02BG02	rimazolium				
<b>N05AX08</b>	<b>risperidone ***</b>	N I	<b>5</b>	<b>mg</b>	orally
<b>N05AX08</b>	<b>risperidone ***</b>	N I	<b>1,8</b>	<b>mg</b>	parent-depot
R01AX05	ritiometan				
N02BA80	salicinum combinations with psycholeptics				
N02BA75	salicylamide, combinations with psycholeptics				
N05CM05	scopolamine				
<b>N05CA06</b>	<b>secobarbital</b>	1971	<b>100</b>	<b>mg</b>	orally
N01AB08	sevoflurane				
N01AX14	s-ketamine				
R01AC05	spaglumic acid				
M03BA30	stiramate, combinations				
M03BA04	styamate				
<b>N01AH03</b>	<b>sufentanil</b>	1961	<b>N A</b>		parenteral
R01AB09	tefazoline				
<b>N05CD07</b>	<b>temazepam</b>	1971	<b>20</b>	<b>mg</b>	orally
<b>M03BX07</b>	<b>tetrazepam</b>	1971	<b>N A</b>		orally
R01AA06	tetryzoline				
R01AB03	tetryzoline				
R05DA10	thebacon	1961			

M03BX05	thiocolchicoside				
N01AF03	thiopental				
N05CA19	thiopental				
R01AC06	thonzylamine				
N06AX14	Tianeptine				
<b>N02AX01</b>	<b>Tilidine</b>	1961			
R05DB24	tipepidine				
R01AD07	tixocortol				
R01AD57	tixocortol, combinations				
M03BX02	tizanidine				
N05BA23	tofisopam				
M03BX04	tolperisone				
N02AX02	tramadol				
N02AX52	tramadol, combinations				
R01AA09	tramazoline				
N06AX05	trazodone				
R01AD11	triamcinolone				
<b>N05CD05</b>	<b>triazolam</b>	1971	<b>0,25</b>	<b>mg</b>	orally
<b>N05CD05</b>	<b>triazolam</b>	1971	<b>0,2</b>	<b>mg</b>	subl
N01AB05	trichloroethylene				
N05CM07	triclofos				
N06AA06	trimipramine				
M09AB52	trypsin, combinations				
N06AX02	tryptophan				
R01AA11	tuaminoheptane				
R01AB08	tuaminoheptane				
R01AA13	tymazoline				
N05CM09	valerian				
N05CM13	valnoctamide				
R01AX10	various and salt solutions				
N06AX16	venlafaxine				
N06AX09	viloxazine				
N02BG05	viminol				
N05CA09	vinbarbital				
N01AA02	vinyl ether				
N05CA08	vinylbital	1971			
R01AA07	xylometazoline				
R01AB06	xylometazoline				
N05CF03	zaleplon	1971			
N02BG08	Ziconotide				
R05DB15	zipeprol	1971			
<b>N05AE04</b>	<b>ziprasidone ***</b>	N I	<b>80</b>	<b>mg</b>	orally
<b>N05AE04</b>	<b>ziprasidone ***</b>	N I	<b>40</b>	<b>mg</b>	parenteral
<b>N05CF02</b>	<b>zolpidem</b>	1971	<b>10</b>	<b>mg</b>	orally
N05CF02	zolpidem	1971			
<b>N05CF01</b>	<b>zopiclone</b>	N I	<b>7,5</b>	<b>mg</b>	orally

### Annex 3: Geographical repartition of the 6 pharmacies networks

Belgium (Density 343.06 h/km2)



France (Density 113.75 h/km2)



Italy (Density 192.93 h/km2)



Netherlands (Density 437.60 h/km2)



Spain (Density 89.16 h/km<sup>2</sup>)



Geographical area in a black circle were those in which a community pharmacies network was implemented for the OSIAP project (actually in Belgium, Italy, Netherlands and Spain).

Sweden (Density 20.01 h/km<sup>2</sup>)



**Annex 4: List of the medications identified in the OSIAP survey in 2006-2007 according to the 2<sup>nd</sup>, 3<sup>rd</sup> and complete Anatomical Therapeutic and Chemical Classification.**

List of the medications identified in the 2006-2007 survey according to the First level of ATC

1st level	ATC code	Title	2006-2007		2006		2007	
			( n = 1220 )		( n = 599 )		( n = 621 )	
1st level			N	%	N	%	N	%
1	N	Nervous system	758	62,13%	373	62,27%	385	62,00%
2	C	Cardiovascular system	103	8,44%	49	8,18%	54	8,70%
3	A	Alimentary tract and metabolism	98	8,03%	54	9,02%	44	7,09%
4	M	Musculo-skeletal system	69	5,66%	33	5,51%	36	5,80%
5	R	Respiratory system	49	4,02%	23	3,84%	26	4,19%
6	G	Genito urinary system and sex hormones	43	3,52%	16	2,67%	27	4,35%
7	D	Dermatologicals	29	2,38%	19	3,17%	10	1,61%
8	J	Antiinfectives for systemic use	19	1,56%	6	1,00%	13	2,09%
9	B	Blood and blood forming organs	14	1,15%	6	1,00%	8	1,29%
10	H	Systemic hormonal preparations, excl. Sex hormones and insulins	14	1,15%	9	1,50%	5	0,81%
11	S	Sensory organs	14	1,15%	5	0,83%	9	1,45%
12	Z	Various	7	0,57%	4	0,67%	3	0,48%
13	L	Antineoplastic and immunomodulating agents	1	0,08%	1	0,17%	0	0,00%
14	P	Antiparasitic products, insecticides and repellents	1	0,08%	1	0,17%	0	0,00%
15	V	Various	1	0,08%	0	0,00%	1	0,16%



List of the medications identified in the 2006-2007 survey according to the Second level of ATC

2nd level	ATC code	Title	2006-2007		2006		2007	
			( n = 1220 )		( n = 599 )		( n = 621 )	
2nd level			N	%	N	%	N	%
1	N05	Psycholeptics	412	33,77%	211	35,23%	201	32,37%
2	N02	Analgesics	173	14,18%	68	11,35%	105	16,91%
3	N06	Psychoanaleptics	87	7,13%	47	7,85%	40	6,44%
4	N07	Other nervous system drugs	56	4,59%	29	4,84%	27	4,35%
5	A02	Drugs for acid related disorders	31	2,54%	19	3,17%	12	1,93%
6	M01	Antiinflammatory and antirheumatic products	30	2,46%	16	2,67%	14	2,25%
7	C03	Diuretics	24	1,97%	11	1,84%	13	2,09%
8	N03	Antiepileptics	24	1,97%	16	2,67%	8	1,29%
9	C10	Lipid modifying agents	22	1,80%	11	1,74%	11	1,77%
10	G03	Sex hormones and modulators of the genital system	22	1,80%	12	2,00%	10	1,61%
11	M03	Muscle relaxants	21	1,72%	10	1,67%	11	1,77%
12	A03	Drugs for functional gastrointestinal disorders	20	1,64%	9	1,50%	11	1,77%
13	C09	Agents acting on the renin-angiotensin system	19	1,56%	7	1,17%	12	1,93%
14	G04	Urologicals	18	1,48%	4	0,67%	14	2,25%
15	R03	Drugs for obstructive airway diseases	18	1,48%	6	1,00%	12	1,93%
16	J01	Antibacterials for systemic use	16	1,31%	5	0,83%	11	1,77%
17	S01	Ophthalmologicals	13	1,07%	4	0,67%	9	1,45%
18	C07	Beta blocking agents	11	0,90%	5	0,83%	6	0,97%
19	D07	Corticosteroids, dermatological preparations	11	0,90%	8	1,34%	3	0,48%
20	R01	Nasal preparations	11	0,90%	6	1,00%	5	0,81%
21	B01	Antithrombotic agents	10	0,82%	5	0,83%	5	0,81%
22	C05	Vasoprotectives	10	0,82%	4	0,67%	6	0,97%
23	H03	Thyroid therapy	10	0,82%	7	1,17%	3	0,48%
24	R06	Antihistamines for systemic use	10	0,82%	5	0,83%	5	0,81%
25	A10	Drugs used in diabetes	9	0,74%	5	0,83%	4	0,64%
26	A12	Mineral supplements	9	0,74%	6	1,00%	3	0,48%
27	R05	Cough and cold preparations	9	0,74%	5	0,83%	4	0,64%
28	A07	Antidiarrheals, intestinal antiinflammatory/antimicrobial agents	8	0,66%	3	0,50%	5	0,81%
29	C08	Calcium channel blockers	8	0,66%	5	0,83%	3	0,48%
30	M02	Topical products for joint and muscular pain	8	0,66%	4	0,67%	4	0,64%
31	M05	Drugs for treatment of bone diseases	8	0,66%	3	0,50%	5	0,81%

32	A06	Laxatives	7	0,57%	4	0,67%	3	0,48%
33	D08	Antiseptics and disinfectants	6	0,49%	2	0,33%	4	0,64%
34	A16	Other alimentary tract and metabolism products	4	0,33%	3	0,50%	1	0,16%
35	C01	Cardiac therapy	4	0,33%	2	0,33%	2	0,32%
36	D10	Anti-acne preparations	4	0,33%	4	0,67%	0	0,00%
37	N04	Anti-parkinson drugs	4	0,33%	1	0,17%	3	0,48%
38	A01	Stomatological preparations	3	0,25%	2	0,33%	1	0,16%
39	A08	Antiobesity preparations, excl.diet products	3	0,25%	1	0,70%	2	0,32%
40	A11	Vitamins	3	0,25%	2	0,33%	1	0,16%
41	B03	Antianemic preparations	3	0,25%	1	0,70%	2	0,32%
42	C04	Pheripheral vasodilators	3	0,25%	3	0,50%	0	0,00%
43	D01	Antifungals for dermatological use	3	0,25%	2	0,33%	1	0,16%
44	D02	Emollients and protectives	3	0,25%	2	0,33%	1	0,16%
45	H02	Corticosteroids for systemic use	3	0,25%	1	0,17%	2	0,32%
46	C02	Antihypertensives	2	0,16%	1	0,17%	1	0,16%
47	D05	Antipsoriatics	2	0,16%	1	0,17%	1	0,16%
48	G01	Gynecological antiinfectives and antiseptics	2	0,16%	0	0,00%	2	0,32%
49	J07	Vaccines	2	0,16%	0	0,00%	2	0,32%
50	M04	Antigout preparations	2	0,16%	0	0,00%	2	0,32%
51	N01	Anesthetics	2	0,16%	1	0,17%	1	0,16%
52	A04	Antiemetics and antinauseants	1	0,08%	0	0,00%	1	0,16%
53	B02	Antihemorrhagics	1	0,08%	0	0,00%	1	0,16%
54	G02	Other gynecologicals	1	0,08%	0	0,00%	1	0,16%
55	H01	pituitary and hypothalamic hormones and analogues	1	0,08%	1	0,17%	0	0,00%
56	J05	Antivirals for systemic use	1	0,08%	1	0,17%	0	0,00%
57	L02	Endocrine therapy	1	0,08%	1	0,17%	0	0,00%
58	P02	Anthelmintics	1	0,08%	1	0,17%	0	0,00%
59	R07	Other respiratory system products	1	0,08%	1	0,17%	0	0,00%
60	S02	Otologicals	1	0,08%	1	0,17%	0	0,00%
61	V03	All other therapeutic products	1	0,08%	0	0,00%	1	0,16%

List of the medications identified in the 2006-2007 survey according to the Third level of ATC

3rd level	ATC code	Title	2006-2007		2006		2007	
			( n = 1220 )		( n = 599 )		( n = 621 )	
3rd level			N	%	N	%	N	%
1	N05B	Anxiolitics	223	18,28%	117	19,53%	106	17,07%
2	N05C	Hypnotics and sedatives	164	13,44%	78	13,02%	86	13,85%
3	N02A	Opioids	125	10,25%	51	8,51%	74	11,92%
4	N06A	Antidepressants	57	4,67%	38	6,34%	19	3,06%
5	N07B	Drugs used in addictive disorders	55	4,51%	29	4,84%	26	4,19%
6	N02B	Other analgesics and antipyretics	40	3,28%	15	2,50%	25	4,03%
7	M01A	Antiinflammatory and antirheumatic products, non steroids	30	2,46%	16	2,67%	14	2,25%
8	A02B	Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	28	2,30%	17	2,84%	11	1,77%
9	N05A	Antipsychotics	25	2,05%	16	2,67%	9	1,45%
10	N06B	Psychostimulants, agents used for ADHD and nootropics	25	2,05%	6	1,00%	19	3,06%
11	N03A	Antiepileptics	24	1,97%	16	2,67%	8	1,29%
12	C10A	Lipid modifying agents, plain	22	1,80%	11	1,84%	11	1,77%
13	M03B	Muscle relaxants, centrally acting agents	20	1,64%	9	1,50%	11	1,77%
14	A03A	Drugs for functional bowel disorders	14	1,15%	6	1,00%	8	1,29%
15	G03B	Androgens	14	1,15%	3	0,50%	11	1,77%
16	R03A	Adrenergics, inhalants	14	1,15%	5	0,83%	9	1,45%
17	G03A	Hormonal contraceptives for systemic use	13	1,07%	6	1,00%	7	1,13%
18	C03C	High-ceiling diuretics	12	0,98%	6	1,00%	6	0,97%
19	B01A	Antithrombotic agents	10	0,82%	5	0,83%	5	0,64%
20	D07A	Corticosteroids, plain	10	0,82%	7	1,17%	3	0,48%
21	H03A	Thyroid preparations	10	0,82%	7	1,17%	3	0,48%
22	R06A	Antihistamines for systemic use	10	0,82%	5	0,83%	5	0,81%
23	C07A	Beta bloking agents	9	0,74%	3	0,50%	6	0,97%
24	J01C	Beta-lactamin antibacterials, penicillins	9	0,74%	2	0,33%	7	1,13%
25	R01A	Decongestants and other nasal preparations for topical use	9	0,74%	5	0,83%	4	0,64%
26	M02A	Topical products for joint and muscular pain	8	0,66%	4	0,67%	4	0,64%
27	N02C	Antimigraine preparations	8	0,66%	2	0,33%	6	0,97%
28	A06A	Laxatives	7	0,57%	4	0,67%	3	0,48%
29	C09C	Angiotensin II antagonists, plain	7	0,57%	3	0,50%	4	0,64%

30	S01E	Antiglaucoma preparations and miotics	7	0,57%	1	0,17%	6	0,97%
31	C03E	Diuretics and potassium-sparing agents in combination	6	0,49%	4	0,67%	2	0,32%
32	C05C	Capillary stabilizing agents	6	0,49%	1	0,17%	5	0,81%
33	C08C	Selective calcium channel blockers with mainly vascular effects	6	0,49%	5	0,83%	1	0,16%
34	R05D	Cough suppressants, excl. combinations with expectorants	6	0,49%	3	0,50%	3	0,48%
35	A07D	Antipropulsives	5	0,41%	3	0,50%	2	0,32%
36	A10B	Blood glucose lowering drugs, excl. Insulins	5	0,41%	4	0,67%	1	0,16%
37	C09D	Angiotensin II antagonists, combinations	5	0,41%	2	0,33%	3	0,48%
38	D08A	Antiseptics and disinfectants	5	0,41%	2	0,33%	3	0,48%
39	M05B	Drugs affecting bone structure and mineralization	5	0,41%	2	0,33%	3	0,48%
40	A03F	Propulsives	4	0,33%	1	0,17%	3	0,48%
41	A10A	Insulins and analogues	4	0,33%	1	0,17%	3	0,48%
42	A16A	Other alimentary tract and metabolism products	4	0,33%	3	0,50%	1	0,16%
43	C03D	Potassium-sparing agents	4	0,33%	1	0,17%	3	0,48%
44	C09B	Ace inhibitors, combinations	4	0,33%	2	0,33%	2	0,32%
45	G04C	Drugs used in benign prostatic hypertrophy	4	0,33%	1	0,17%	3	0,48%
46	N04A	Anticholinergics agents	4	0,33%	1	0,17%	3	0,48%
47	N06D	Anti-dementia drugs	4	0,33%	3	0,50%	1	0,16%
48	A01A	Stomatological preparations	3	0,25%	2	0,33%	1	0,16%
49	A02A	Antiacids	3	0,25%	2	0,33%	1	0,16%
50	A08A	Antiobesity preparations, excl. diet products	3	0,25%	1	0,17%	2	0,32%
51	A12B	Potassium	3	0,25%	3	0,50%	0	0,00%
52	A12C	Other mineral supplements	3	0,25%	1	0,17%	2	0,32%
53	C04A	Peripheral vasodilators	3	0,25%	3	0,50%	0	0,00%
54	C05A	Agents for treatment of hemorrhoids and anal fissures for topical use	3	0,25%	2	0,33%	1	0,16%
55	C09A	Ace inhibitors, plain	3	0,25%	0	0,00%	3	0,48%
56	D01A	Antifungals for topical use	3	0,25%	2	0,33%	1	0,16%
57	D02A	Emollients and protectives	3	0,25%	2	0,33%	1	0,16%
58	D10A	Anti-acne preparations for topical use	3	0,25%	3	0,50%	0	0,00%
59	G03C	Estrogens	3	0,25%	3	0,50%	0	0,00%
60	G03D	Progestogens	3	0,25%	2	0,33%	1	0,16%
61	H02A	Corticosteroids for systemic use, plain	3	0,25%	1	0,17%	2	0,32%
62	J01D	Other beta-lactam antibacterials	3	0,25%	1	0,17%	2	0,32%
63	R03B	Other drugs for obstructive airway diseases, inhalants	3	0,25%	1	0,17%	2	0,32%

64	A07A	Intestinal antiinfectives	2	0,16%	0	0,00%	2	0,32%
65	A12A	Calcium	2	0,16%	1	0,17%	1	0,16%
66	B03A	Iron preparations	2	0,16%	1	0,17%	1	0,16%
67	C01E	Other cardiac preparations	2	0,16%	1	0,17%	1	0,16%
68	C03B	Low-ceiling diuretics, excl.thiazides	2	0,16%	0	0,00%	2	0,32%
69	C07B	Beta bloking agents and thiazides	2	0,16%	2	0,33%	0	0,00%
70	C08D	Selective calcium channel blockers with direct cardiac effects	2	0,16%	0	0,00%	2	0,32%
71	D05A	Antipsoriatics for topical use	2	0,16%	1	0,17%	1	0,16%
72	G01A	Antiinfectives and antiseptics, excl.combinations with corticosteroids	2	0,16%	0	0,00%	2	0,32%
73	G03H	Antiandrogens	2	0,16%	1	0,17%	1	0,16%
74	J01F	Macrolides, lincosmides and Stretogramins	2	0,16%	0	0,00%	2	0,32%
75	J01X	Other antibacterials	2	0,16%	2	0,33%	0	0,00%
76	M04A	Antigout preparations	2	0,16%	0	0,00%	2	0,32%
77	N01B	Anesthetics, local	2	0,16%	1	0,17%	1	0,16%
78	R01B	Nasal decongestants for systemic use	2	0,16%	1	0,17%	1	0,16%
79	R05F	Cough suppressants and expectorants, combinations	2	0,16%	1	0,17%	1	0,16%
80	S01G	Decongestants and antiallergics	2	0,16%	1	0,17%	1	0,16%
81	S01X	Other ophthalmologicals	2	0,16%	2	0,33%	0	0,00%
82	A03C	Antispasmodics in combination with psycholeptics	1	0,08%	1	0,17%	0	0,00%
83	A03E	Antispasmodics and anticholinergics in combination with other drugs	1	0,08%	1	0,17%	0	0,00%
84	A04A	Antiemetics and antinauseants	1	0,08%	0	0,00%	1	0,16%
85	A07X	Other antidiarrheals	1	0,08%	0	0,00%	1	0,16%
86	A11C	Vitamin A and D, incl. combination of the two	1	0,08%	0	0,00%	1	0,16%
87	A11E	Vitamin B-complex, incl. Combinations	1	0,08%	1	0,17%	0	0,00%
88	B02B	Vitamin K and other hemostatics	1	0,08%	0	0,00%	1	0,16%
89	B03B	Vitamin B12 and folic acid	1	0,08%	0	0,00%	1	0,16%
90	C01B	Antiarrhythmins, class I ans III	1	0,08%	1	0,17%	0	0,00%
91	C01D	Vasodilators used in cardiac diseases	1	0,08%	0	0,00%	1	0,16%
92	C02A	Antiadrenergic agents, centrally acting	1	0,08%	0	0,00%	1	0,16%
93	C02C	Antiadrenergic agents, peripherally acting	1	0,08%	1	0,17%	0	0,00%
94	D07C	Corticosteroids, combinaions with antibiotics	1	0,08%	1	0,17%	0	0,00%
95	D10B	Anti-acne preparations for systemic use	1	0,08%	1	0,17%	0	0,00%
96	G02C	Other gynecologicals	1	0,08%	0	0,00%	1	0,16%

97	G03F	Progestogens and estrogens in combination	1	0,08%	0	0,00%	1	0,16%
98	H01A	Anterior pituitary lobe hormones and analogues	1	0,08%	1	0,17%	0	0,00%
99	J05A	Direct acting antivirals	1	0,08%	1	0,17%	0	0,00%
100	J07B	Viral vaccines	1	0,08%	0	0,00%	1	0,16%
101	J07C	Bacterials and viral vaccines, combined	1	0,08%	0	0,00%	1	0,16%
102	L02B	Hormone antagonists and related agents	1	0,08%	1	0,17%	0	0,00%
103	M03A	Muscle relaxants, peripherally acting agents	1	0,08%	1	0,17%	0	0,00%
104	N06C	Psycholeptics and psychoanaleptics in combination	1	0,08%	0	0,00%	1	0,16%
105	N07C	Antivertigo preparations	1	0,08%	0	0,00%	1	0,16%
106	P02C	Antinematodal agents	1	0,08%	1	0,17%	0	0,00%
107	R03D	Other systemic drugs for obstructive airway diseases	1	0,08%	0	0,00%	1	0,16%
108	R05C	Expectorants, excl. combinations with cough suppressants	1	0,08%	1	0,17%	0	0,00%
109	R07A	Other respiratory system products	1	0,08%	1	0,17%	0	0,00%
110	S01B	Antiinflammatory agents	1	0,08%	0	0,00%	1	0,16%
111	S01C	Antiinflammatory agents and antiinfectives in combination	1	0,08%	0	0,00%	1	0,16%
112	S02B	Corticosteroids	1	0,08%	1	0,17%	0	0,00%
113	V03A	All other therapeutic products	1	0,08%	0	0,00%	1	0,16%
114	.	Missing value	14	1,15%	8	1,34%	6	0,96%

List of the medications identified in the 2006-2007 survey according to the Second level of ATC, Nervous System Class

<b>2nd level</b>	<b>ATC code</b>	<b>Title</b>	<b>2006-2007</b>		<b>2006</b>		<b>2007</b>	
<b>N</b>	<b>2nd level</b>		<b>( n = 758 )</b>		<b>( n = 373 )</b>		<b>( n = 385 )</b>	
			N	%	N	%	N	%
1	N05	Psycholeptics	412	54,35%	211	56,57%	201	52,21%
2	N02	Analgesics	173	22,82%	68	18,23%	105	27,27%
3	N06	Psychoanaleptics	87	11,48%	47	12,60%	40	10,39%
4	N07	Other nervous system drugs	56	7,39%	29	7,77%	27	7,01%
5	N03	Antiepileptics	24	3,17%	16	4,29%	8	2,08%
6	N04	Anti-parkinson drugs	4	0,53%	1	0,27%	3	0,78%
7	N01	Anesthetics	2	0,26%	1	0,27%	1	0,26%

List of the medications identified at least 2 times in the 2006-2007 survey according to the ATC classification

	<i>ATC code</i>	<i>DCI</i>	<i>2006-2007</i>		<i>2006</i>		<i>2007</i>	
			<i>( n = 1050 )</i>		<i>( n = 522 )</i>		<i>( n = 528 )</i>	
			N	%	N	%	N	%
1	N05CF02	Zolpidem	68	6,48%	36	6,90%	32	6,06%
2	N05BA08	Bromazepam	60	5,71%	39	7,47%	21	3,98%
3	N05BA12	Alprazolam	60	5,71%	27	5,17%	33	6,25%
4	N07BC01	Buprenorphine	49	4,67%	25	4,79%	24	4,55%
5	N02AA59	Codeine, combinations excl. psycholeptics	45	4,29%	11	2,11%	34	6,44%
6	N05CF01	Zopiclone	42	4,00%	16	3,07%	26	4,92%
7	N02BE01	Paracetamol	33	3,14%	14	2,68%	19	3,60%
8	N02AX02	Tramadol	31	2,95%	12	2,30%	19	3,60%
9	N05BA06	Lorazepam	31	2,95%	13	2,49%	18	3,41%
10	N06BA04	Methylphenidate	25	2,38%	6	1,15%	19	3,60%
11	N05CD03	Flunitrazepam	24	2,29%	15	2,87%	9	1,70%
12	N05BA04	Oxazepam	21	2,00%	13	2,49%	8	1,52%
13	N05BA05	Potassium clorazepate	20	1,90%	8	1,53%	12	2,27%
14	N05CD06	Lormetazepam	16	1,52%	5	0,96%	11	2,08%
15	N03AE01	Clonazepam	15	1,43%	11	2,11%	4	0,76%
16	N02AC54	Dextropropoxyphene, comb. excl. psycholeptics	14	1,33%	7	1,34%	7	1,33%
17	C03CA01	Furosemide	12	1,14%	6	1,15%	6	1,14%
18	N02AA01	Morphine	12	1,14%	9	1,72%	3	0,57%
19	N05BA01	Diazepam	12	1,14%	6	1,15%	6	1,14%
20	M03BX07	Tetrazepam	11	1,05%	4	0,77%	7	1,33%
21	M01AE01	Ibuprofen	10	0,95%	7	1,34%	3	0,57%
22	H03AA01	Levothyroxine sodium	9	0,86%	7	1,34%	2	0,38%
23	N06AB05	Paroxetine	9	0,86%	6	1,15%	3	0,57%
24	N06AX16	Venlafaxine	9	0,86%	5	0,96%	4	0,76%
25	C10AX04	Benfluorex	8	0,76%	4	0,77%	4	0,76%
26	N06AB03	Fluoxetine	8	0,76%	8	1,53%	0	0,00%
27	N06AX14	Tianeptine	8	0,76%	4	0,77%	4	0,76%
28	D07AC01	Betamethasone	7	0,67%	6	1,15%	1	0,19%
29	N05AA06	Cyamemazine	7	0,67%	7	1,34%	0	0,00%
30	A02BB01	Misoprostol	6	0,57%	5	0,96%	1	0,19%
31	A02BC01	Omeprazole	6	0,57%	2	0,38%	4	0,76%



32	B01AC06	Acetylsalicylic acid	6	0,57%	4	0,77%	2	0,38%
33	C10AA05	Atorvastatin	6	0,57%	2	0,38%	4	0,76%
34	J01CA04	Amoxicillin	6	0,57%	1	0,19%	5	0,95%
35	N02AB03	Fentanyl	6	0,57%	2	0,38%	4	0,76%
36	N05CD11	Loprazolam	6	0,57%	3	0,57%	3	0,57%
37	R03AC02	Salbutamol	6	0,57%	2	0,38%	4	0,76%
38	A02BC05	Esomeprazole	5	0,48%	4	0,77%	1	0,19%
39	A03AX12	Phloroglucinol	5	0,48%	3	0,57%	2	0,38%
40	A07DA03	Loperamide	5	0,48%	3	0,57%	2	0,38%
41	G03AB03	Levonorgestrel and estrogen	5	0,48%	2	0,38%	3	0,57%
42	G04BE03	Sildenafil	5	0,48%	1	0,19%	4	0,76%
43	G04BE09	Vardenafil	5	0,48%	1	0,19%	4	0,76%
44	M03BA02	Carisoprodol	5	0,48%	2	0,38%	3	0,57%
45	N05BC01	Meprobamate	5	0,48%	2	0,38%	3	0,57%
46	N05BC51	Mebromate, combinations	5	0,48%	3	0,57%	2	0,38%
47	N06AB06	Sertraline	5	0,48%	4	0,77%	1	0,19%
48	N06AX11	Mirtazapine	5	0,48%	4	0,77%	1	0,19%
49	N07BC02	Methadone	5	0,48%	3	0,57%	2	0,38%
50	A02BC02	Pantoprazole	4	0,38%	1	0,19%	3	0,57%
51	A03AA05	Trimebutine	4	0,38%	1	0,19%	3	0,57%
52	A03FA03	Domperidone	4	0,38%	1	0,19%	3	0,57%
53	B01AC04	Clopidogrel	4	0,38%	1	0,19%	3	0,57%
54	C03DA01	Spirolactone	4	0,38%	1	0,19%	3	0,57%
55	C03EA01	Hydrochlorothiazide and potassium-sparing agents	4	0,38%	3	0,57%	1	0,19%
56	C09CA07	Telmisartan	4	0,38%	2	0,38%	2	0,38%
57	M01AB05	Diclofenac	4	0,38%	3	0,57%	1	0,19%
58	M02AA10	Ketoprofen	4	0,38%	3	0,57%	1	0,19%
59	M02AA15	Diclofenac	4	0,38%	1	0,19%	3	0,57%
60	N02AA08	Dihydrocodeine	4	0,38%	2	0,38%	2	0,38%
61	N02AC04	Dextropropoxyphene	4	0,38%	2	0,38%	2	0,38%
62	N02AX52	Tramadol, combinations	4	0,38%	1	0,19%	3	0,57%
63	N02BE71	Paracetamol, combinations with psycholeptics	4	0,38%	0	0,00%	4	0,76%
64	N05BB01	Hydroxyzine	4	0,38%	3	0,57%	1	0,19%
65	N06AB04	Citalopram	4	0,38%	3	0,57%	1	0,19%
66	R01AD11	Triamcinolone	4	0,38%	2	0,38%	2	0,38%

67	A02BC03	Lansoprazole	3	0,29%	3	0,57%	0	0,00%
68	A02BC04	Rabéprazole	3	0,29%	2	0,38%	1	0,19%
69	A03AA04	Mebeverine	3	0,29%	1	0,19%	2	0,38%
70	A06AD65	Macrogol, combinations	3	0,29%	2	0,38%	1	0,19%
71	A10BA02	Metformin	3	0,29%	2	0,38%	1	0,19%
72	A12BA01	Potassium chloride	3	0,29%	3	0,57%	0	0,00%
73	A12CC08	Magnesium	3	0,29%	1	0,19%	2	0,38%
74	C05CA53	Diosmin, combinations	3	0,29%	0	0,00%	3	0,57%
75	C05CA54	Troxerutin, combinations	3	0,29%	1	0,19%	2	0,38%
76	C07AB03	Atenolol	3	0,29%	1	0,19%	2	0,38%
77	C08CA01	Amlodipine	3	0,29%	2	0,38%	1	0,19%
78	C10AB05	Fenofibrate	3	0,29%	2	0,38%	1	0,19%
79	D02AC	Soft paraffin and fat products	3	0,29%	2	0,38%	1	0,19%
80	G03AA10	Gestodene and estrogen	3	0,29%	3	0,57%	0	0,00%
81	G03DB01	Dydrogesterone	3	0,29%	2	0,38%	1	0,19%
82	G04BE08	Tadalafil	3	0,29%	0	0,00%	3	0,57%
83	M03BA52	Carisoprodol, combinations excl. psycholeptics	3	0,29%	2	0,38%	1	0,19%
84	N02AA05	Oxycodone	3	0,29%	3	0,57%	0	0,00%
85	N02CA01	Dihydroergotamine	3	0,29%	0	0,00%	3	0,57%
86	N05AH03	Olanzapine	3	0,29%	3	0,57%	0	0,00%
87	N05AH04	Quetiapine	3	0,29%	1	0,19%	2	0,38%
88	N05AL05	Amisulpride	3	0,29%	2	0,38%	1	0,19%
89	N05BA11	Prazepam	3	0,29%	1	0,19%	2	0,38%
90	N06DX02	Ginkgo Biloba	3	0,29%	2	0,38%	1	0,19%
91	R01AD52	Prednisolone, combinations	3	0,29%	2	0,38%	1	0,19%
92	R03AC13	Formoterol	3	0,29%	1	0,19%	2	0,38%
93	R03AK06	Salmeterol and other drugs for obstructive airway diseases	3	0,29%	0	0,00%	3	0,57%
94	R06AX27	Desloratadine	3	0,29%	1	0,19%	2	0,38%
95	A02AH	Antacids with sodium bicarbonate	2	0,19%	2	0,38%	0	0,00%
96	A03AX04	Pinaverium	2	0,19%	1	0,19%	1	0,19%
97	A06AD11	Lactulose	2	0,19%	1	0,19%	1	0,19%
98	A07AX03	Nifuroxazide	2	0,19%	0	0,00%	2	0,38%
99	A08AA10	Sibutramine	2	0,19%	1	0,19%	1	0,19%
100	A10AB05	Insulin aspart	2	0,19%	0	0,00%	2	0,38%

101	A10BB09	Gliclazide	2	0,19%	2	0,38%	0	0,00%
102	A16AX02	Anethole trihione	2	0,19%	1	0,19%	1	0,19%
103	C01EB15	Trimetazidine	2	0,19%	1	0,19%	1	0,19%
104	C03EB01	Furosemide and potassium-sparing agents	2	0,19%	1	0,19%	1	0,19%
105	C05AX03	Other preparations, combinations	2	0,19%	2	0,38%	0	0,00%
106	C07AB02	Metoprolol	2	0,19%	2	0,38%	0	0,00%
107	C07BB07	Bisoprolol and thiazides	2	0,19%	2	0,38%	0	0,00%
108	C08CA13	Lercanidipine	2	0,19%	2	0,38%	0	0,00%
109	C08DA01	Verapamil	2	0,19%	0	0,00%	2	0,38%
110	C09AA04	Perindopril	2	0,19%	0	0,00%	2	0,38%
111	C09DA04	Irbesartan and diuretics	2	0,19%	1	0,19%	1	0,19%
112	C10AA01	Simvastatin	2	0,19%	2	0,38%	0	0,00%
113	C10AA03	Pravastatin	2	0,19%	1	0,19%	1	0,19%
114	D01AC03	Econazole	2	0,19%	1	0,19%	1	0,19%
115	D07AB08	Desonide	2	0,19%	1	0,19%	1	0,19%
116	D08AC02	Chlorhexidine	2	0,19%	1	0,19%	1	0,19%
117	D08AC52	Chlorhexidine, combinations	2	0,19%	0	0,00%	2	0,38%
118	G03AA07	Levonorgestrel and estrogen	2	0,19%	0	0,00%	2	0,38%
119	G03AC09	Desogestrel	2	0,19%	0	0,00%	2	0,38%
120	G03CA03	Estradiol	2	0,19%	2	0,38%	0	0,00%
121	G03HB01	Cyproterone and estrogen	2	0,19%	1	0,19%	1	0,19%
122	J01CR02	Amoxicillin and enzyme inhibitor	2	0,19%	1	0,19%	1	0,19%
123	J01DD13	Cefpodoxime	2	0,19%	1	0,19%	1	0,19%
124	J01XC01	Fusidic acid	2	0,19%	2	0,38%	0	0,00%
125	M01AC01	Piroxicam	2	0,19%	2	0,38%	0	0,00%
126	M01AX02	Niflumic acid	2	0,19%	0	0,00%	2	0,38%
127	M04AA01	Allopurinol	2	0,19%	0	0,00%	2	0,38%
128	M05BA07	Risedronic acid	2	0,19%	0	0,00%	2	0,38%
129	N01BB20	Combinations: lidocaine et prilocaine	2	0,19%	1	0,19%	1	0,19%
130	N02BG06	Nefopam	2	0,19%	1	0,19%	1	0,19%
131	N02CC02	Naratriptan	2	0,19%	0	0,00%	2	0,38%
132	N02CC06	Eletriptan	2	0,19%	2	0,38%	0	0,00%
133	N03AA02	Phenobarbital	2	0,19%	1	0,19%	1	0,19%
134	N03AG01	Valproic acid	2	0,19%	1	0,19%	1	0,19%
135	N03AG02	Valpromide	2	0,19%	1	0,19%	1	0,19%

136	N03AX12	Gabapentin	2	0,19%	2	0,38%	0	0,00%
137	N04AA01	Trihexyphenidyl	2	0,19%	0	0,00%	2	0,38%
138	N05AL03	Tiapride	2	0,19%	1	0,19%	1	0,19%
139	N05AX08	Risperidone	2	0,19%	0	0,00%	2	0,38%
140	N05CF03	Zaleplon	2	0,19%	0	0,00%	2	0,38%
141	N05CM02	Clomethiazole	2	0,19%	2	0,38%	0	0,00%
142	N06AA04	Clomipramine	2	0,19%	2	0,38%	0	0,00%
143	N06AB10	Escitalopram	2	0,19%	1	0,19%	1	0,19%
144	R03AK07	Formoterol and other drugs for obstructive airway diseases	2	0,19%	2	0,38%	0	0,00%
145	R03BA02	Budesonide	2	0,19%	1	0,19%	1	0,19%
146	R05DA10	Thebacon	2	0,19%	2	0,38%	0	0,00%
147	R05FA02	Opium derivatives and expectorants	2	0,19%	1	0,19%	1	0,19%
148	R06AD01	Alimemazine	2	0,19%	1	0,19%	1	0,19%
149	S01EA05	Brimonidine	2	0,19%	0	0,00%	2	0,38%
150	S01ED51	Timolol, combinations	2	0,19%	0	0,00%	2	0,38%
151	S01EE01	Latanoprost	2	0,19%	1	0,19%	1	0,19%

## Annex 5: oral communications and posters about the Osiap Europe project.

2006

10th Annual Meeting of the French Society of Pharmacology and Therapeutics ; 10-12 April 2006 (Montpellier, France)  
Fundamental and Clinical Pharmacology 2006 , vol 20, issue 2, p145-234

22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Lisbon, Portugal, 24-27 August 2006  
Pharmacoepidemiology and Drug Safety 2006 Vol 15 issue S1, p S1-S316

**Le projet OSIAP EUROPE :**  
Présentation d'une étude pharmacoépidémiologique européenne sur le détournement d'usage des médicaments commercialisés

M Lapeyre Mestre; M Gony et le réseau des CEIP, France.  
U Bergman, Suède. A Carvajal; D Macías, Espagne.  
A Conforti, Italie. ER Heerdink, Pays-Bas.  
R Vander Stichele, Belgique.



**The OSIAP Europe project :**  
Presentation of a European pharmacoepidemiological survey of the misuse or abuse of marketed drugs

M Lapeyre-Mestre<sup>1</sup>; M Gony<sup>1</sup>; U Bergman<sup>2</sup>; A Carvajal<sup>3</sup>; A Conforti<sup>4</sup>; ER Heerdink<sup>5</sup>; D Macías<sup>6</sup>; R Vander Stichele<sup>1</sup>  
1. Unit of Pharmacoepidemiology EA3856, CEIP, Toulouse, France; 2 Karolinska Institute - Dept of Physiology & Pharmacology, Stockholm, Sweden; 3 Instituto de Farmacoepidemiología, Valladolid, Spain; 4 Regional Pharmacovigilance Center, Verona, Italy; 5 Department of Pharmacoepidemiology, Utrecht, Netherlands; 6 Myriasis Institute of Pharmacology, Ghent, Belgium.

**Introduction**  
Data concerning drug abuse liability are habitually pointed out by experimental and clinical studies, but remain often insufficient when the drug is widely used in the real life. Following the report of Bergman et al in 1989, the French network of Centres d'Evaluation et d'Information sur la Pharmacodépendance (CEIP) has begun a prescription forgery survey with 11 community pharmacies networks in France. This system called OSIAP (Ordonnances Suspectes Indicateur d'Abus Possible), provides information about potential abuse liability of marketed drugs in France. In 2003, the Public Health Program of the European Commission approved a collaborative project which aims to extend the OSIAP system in Europe. We present the first steps of this European project which began in January 2005.

**Aims of the project**

- To identify in a systematic, reproducible and periodic way marketed drugs which are misuse and/or abuse
- To develop a pharmaco-epidemiologic index allowing to assess the abuse potential for a specific drug (calculation of a diversion ratio).
- To compare spatial and temporal trends of marketed drug diversion and to assess the impact of regulatory measures.

**Methods**

**Monitoring network of drug diversion from community pharmacies**  
Identification of suspect prescription forms according to a list of predefined falsification or suspicion criteria  
For each identified marketed drug, calculation of a "diversion ratio", defined by the number of citations for this drug divided by the sales of this drug during the same period and in the same geographical area.

**Participating countries**



**On-going of the project**  
The first step was an inventory in each participating country, of the number and the re-orientation of community pharmacies, the availability of drug sales data.  
The second step consists in the preparation of a registry of all prescription only medicines and their status in each country (for example, narcotic, psychotropic or any drug with a special rule of prescription and/or delivery). The third step which is going on is the constitution of voluntary pharmacies networks in each country.

**Inventory**

**Drug prescribers :**  
Medical doctors in all countries (midwives, dentists...)  
Private or public system  
Medical density varies (from 25 in Netherlands to 43/10,000 inhabitants in Spain)

**Drug delivery**  
Pharmacies  
Density from 1 in Sweden to 5/10,000 inhabitants in Belgium  
Drug sales  
Available in all countries (national sales data)  
Medications registry (all P-OA available in community pharmacies, with specific rules of prescription and/or delivery)

- Different drugs available :
  - fampridone, clobazepam, domnamol
- Different scheduling scheme :
  - ex methylphenidate
- Different medical indications (solite maintenance drugs)
- Different rules : specific prescription form for narcotics

**Preliminary results (spring 2006)**

- Networks of voluntary community pharmacies:
  - France : 160 pharmacies (8%)
  - Spain : 31 voluntary pharmacies among 300 recruited in the province of Castilla 3 León
  - Italy : 30 voluntary pharmacies among 100 recruited in the Region of Marche
  - Belgium : 27 pharmacies (2% of pharmacies in Flanders)
- Common list of suspicion criteria
- First data collection in May 2006



**Conclusion**  
The first period of suspect prescriptions collection has been done during Spring 2006, and will allow a first European comparison of marketed drug diversion. We expect to validate a permanent and reproducible measurement tool to assess the impact of preventive measures (warning to prescribers, rules of prescription or dispensing, scheduling of drugs...).

2007 :

11th Annual Meeting of the French Society of Pharmacology and Therapeutics ; 11-13 April 2007 (Toulouse, France)  
 Fundamental and Clinical Pharmacology 2007, Vol 21, supplement 1, p1-113

**ETUDE OSIAP EUROPE** CEIP

M. Laurent Meestre (1), M. Heger (2), U. Bonmann (3), A. Cervoni (4), R. Corforn (5), R. Heerdink (6), D. Maroz (7), R. Vander Stichele (8)

**Le système OSIAP** (Ordonnances Suspectes Indicateurs d'Abus et de Pharmacodépendance) permet d'identifier les médicaments détournés à partir du recueil d'ordonnances falsifiées présentées en pharmacie d'officine. Il repose en France, sur des réseaux territoriaux de pharmaciens d'officine, unifiés par les CEIP et leurs centres correspondants.

**OBJECTIFS :**

- Étendre le système OSIAP à plusieurs pays européens (Belgique, Pays-Bas, Espagne, Italie, Suède).
- Identifier dans ces pays de façon standardisée et reproductible, le message ou potentiel d'abus des médicaments commercialisés.
- Comparer les résultats obtenus dans les différents pays et l'impact des différentes règles de prescription sur le détournement des médicaments.

**METHODE :**

- Recueil des ordonnances suspectes par des pharmaciens volontaires dans différents pays européens.
- Formulaires de recueil, périodes d'enquête et critères de suspicion, communs à ces pays.
- Caducé par pays de base de détournement de chaque médicament (nombre de critères de ce médicament, rapporté au nombre de ventes durant la même période), inscrit en base de données journalière (DDJ).

**Préparation et mise en place du recueil de données :**

- Harmonisation des outils méthodologiques et de la DDJ.
- Proposition d'un formulaire de recueil pour les pharmaciens.
- Adoption d'une liste commune de critères permettant l'identification d'une ordonnance falsifiée (modification de la posologie ou de la durée de traitement - report d'un médicament - prescription non conforme à la spécialité - ordonnance pharmaceutique - ordonnance vide - ordonnance falsifiée (photocopie, mauvaise...), pharmacien - patient - demandeur ou prescripteur reconnu de pharmacien...)
- Élaboration d'un registre des médicaments (en Déclaration Commune Internationale), qui présentent un potentiel d'abus ou de pharmacodépendance et sont disponibles en pharmacie d'officine dans les six ou sept pays participants.
- Recueil par chaque pays de DDJ, des règles relatives de prescription et de délivrance.
- Recueil du nombre de DDJ par boîte, pour toutes les spécialités correspondantes.
- Constitution par chaque pays d'un réseau de pharmaciens volontaires et information aux pharmaciens.
- Déroulement de la première enquête - mai 2006.

**PREMIERS RESULTATS**

Étude de base : Densité médicale de 25 (sur Pays-Bas) à 43/1000 ha (Espagne) Densité des officines de 1 (Suède) à 5/100 000 ha (Belgique), (Roumanie), (mais avec les classifications (habitations) et les données de prescription (prescriptions)).

Réseaux de pharmacies et nombre d'OSIAP recueillis

Nombre de pharmacies	Premier recueil	Deuxième recueil
Belgique	209	21
Espagne	240	30
Italie	300	1
Pays Bas	260	0
Suède	880	880
France	2240	199

DDJ créées dans les différents pays lors du 1<sup>er</sup> recueil :

VII Jornadas De Farmacovigilancia Cáceres 22 Y 23 De Marzo De 2007

OSIAP. proyecto europeo para identificar el potencial de abuso de los medicamentos  
 diego macias <sup>1</sup>; alfonso carvajal <sup>2</sup>; maryse lapeyre-mestre <sup>3</sup>; mireille gony <sup>4</sup>; ulf bergman <sup>5</sup>; anita conforti <sup>6</sup>; eibert r heerdink <sup>7</sup>; robert vander stichele <sup>8</sup>.

<sup>1</sup> Instituto de farmacoepidemiología, universidad de valladolid. <sup>2</sup> Unité de pharmacoepidemiologie, université paul sabatier (toulouse). <sup>3</sup> Karolinska institutet, division of clinical pharmacology, huddinge university hospital, stockholm. <sup>4</sup> Dipartimento di medicina e sanità pubblica, sezione di farmacologia, università degli studi di verona. <sup>5</sup> Department of pharmacoepidemiology, utrecht university. <sup>6</sup> Heymans institute of pharmacology, ghent university.

objetivo. Valorar el potencial de abuso de los medicamentos a través de las recetas falsas que se reciben en las oficinas de farmacia.

resultados. El primer periodo de recogida se realizó en mayo de 2006, participaron un total de 1819 farmacias en toda Europa y se recogieron 248 recetas falsificadas. La media de edad en los individuos que presentaban receta falsificada fue de 49 años (16 - 90) en Francia y de 37 (20 - 58) en España; entre estos individuos se ha observado un mayor porcentaje de mujeres en Francia (82%) y en Bélgica (55%), en España, por el contrario, el porcentaje ha sido del 39 %. En las 216 prescripciones recogidas figuraban 314 medicamentos de los cuales el 60 % pertenecían al grupo de fármacos del SNC (tabla 2). Los fármacos que se hallaron en las recetas alteradas en 2 o más países se muestran en la figura.

método. Se han establecido redes de farmacias voluntarias, en los distintos países que participan en el proyecto con objeto de identificar las recetas falsas (alteradas, sustraídas, falsificadas,...). El número de farmacias participantes aparece reflejado en la tabla 1. Se ha utilizado un cuestionario sencillo y uniforme para la recogida de la información de estos casos de falsificación.


tabla 1. Red europea de farmacias voluntarias

	número de farmacias totales	farmacias contactadas	farmacias reclutadas
Belgica	2200	133	199
Italia	17350	200	30
Holanda	1730	240	40
España	20340	240	31
Suecia	900	900	880
Francia	22600	2262	2262

tabla 2. Recetas falsificadas en función del grupo farmacológico.

grupo farmacológico	Belgica	Italia	Francia	España
antibióticos	2	1	41	21
antipsicóticos	4	1	30	6
analgésicos opiáceos	1	1	16	2
psicoestimulantes	2	1	11	6
anticoagulantes (mantenimiento)	1	1	13	1
anticoagulantes	2	1	10	1
anticoagulantes	1	1	8	1

Fig. Fármacos presentes en las recetas sospechosas de 2 o más países



Conclusiones. Existen diferencias, dependiendo del país, en las reglas de prescripción y dispensación de los fármacos con potencial de abuso, así como en la oferta de estos medicamentos. Los fármacos más afectados por las falsificaciones son los del grupo de analgésicos e hipnóticos, aunque el principio activo más falsificado varía de un país a otro. Este sistema de recogida de datos es capaz de detectar el potencial de abuso de sustancias para el que esta reacción se desconocía.

5<sup>èmes</sup> Ateliers de la Pharmacodependance 22 - 23 octobre 2007 Biarritz, France

**OSIAP EUROPE: Résultats intermédiaires** CEIP

M. Laurent Meestre (1), M. Heger (2), U. Bonmann (3), A. Cervoni (4), R. Corforn (5), R. Heerdink (6), D. Maroz (7), R. Vander Stichele (8)

**Le système OSIAP** (Ordonnances Suspectes Indicateurs d'Abus et de Pharmacodépendance) permet d'identifier les médicaments détournés à partir du recueil d'ordonnances falsifiées présentées en pharmacie d'officine. Il repose en France, sur des réseaux territoriaux de pharmaciens d'officine, unifiés par les CEIP.

**OBJECTIFS :**

- Étendre le système OSIAP à plusieurs pays européens (Belgique, Pays-Bas, Espagne, Italie, Suède).
- Identifier dans ces pays de façon standardisée et reproductible, le message ou potentiel d'abus des médicaments commercialisés.
- Comparer les résultats obtenus dans les différents pays et l'impact des différentes règles de prescription sur le détournement des médicaments.

**METHODE :**

- Recueil des ordonnances suspectes par des pharmaciens volontaires dans différents pays européens.
- Formulaires de recueil et critères de suspicion, communs à ces pays. 3 périodes d'enquête d'un mois chacune.
- Caducé par pays de base de détournement de chaque médicament (nombre de critères de ce médicament, rapporté au nombre de ventes durant la même période), inscrit en base de données journalière (DDJ).

**Harmonisation des outils méthodologiques et mise en place du recueil de données :**

- Proposition d'un formulaire de recueil pour les pharmaciens.
- Adoption d'une liste commune de critères permettant l'identification d'une ordonnance falsifiée (modification de la posologie ou de la durée de traitement - report d'un médicament - prescription non conforme à la spécialité - ordonnance pharmaceutique - ordonnance vide - ordonnance falsifiée (photocopie, mauvaise...), pharmacien - patient - demandeur ou prescripteur reconnu de pharmacien...)
- Élaboration d'un registre des médicaments (en Déclaration Commune Internationale), qui présentent un potentiel d'abus ou de pharmacodépendance et sont disponibles en pharmacie d'officine dans les six ou sept pays participants.
- Recueil par chaque pays de DDJ, des règles relatives de prescription et de délivrance.
- Recueil du nombre de DDJ par boîte, pour toutes les spécialités correspondantes.
- Constitution par chaque pays d'un réseau de pharmaciens volontaires et information aux pharmaciens.

**RESULTATS des deux premiers recueils**

Nombre de pharmacies dans les réseaux de pharmacies participantes et d'OSIAP recueillis

	Premier recueil (Printemps 2006)		Deuxième recueil (Hiver 2006)	
	Réseau	Participants OSIAP	Réseau	Participants OSIAP
Belgique	209	34	13	21
Espagne	240	31	39	30
Italie	300	30	1	40
Pays Bas	260	22	0	110
Suède	880	880	880	880
France	2240	900	169	2275

DDJ créées dans trois pays lors des 1<sup>er</sup> et 2<sup>èmes</sup> recueils :

This report was produced by a contractor for Health & Consumer Protection Directorate General and represents the views of the contractor or author. These views have not been adopted or in any way approved by the Commission and do not necessarily represent the view of the Commission or the Directorate General for Health and Consumer Protection. The European Commission does not guarantee the accuracy of the data included in this study, nor does it accept responsibility for any use made thereof.